(NewsUSA) - For many people, breast cancer screening becomes a priority around age 40. However, according to recommendations from the American College of Radiology^® (ACR^®), one of the most important conversations about breast health should happen much sooner: a breast cancer risk assessment by age 25.

(Mitch Jelniker) - For people diagnosed with small cell lung cancer, the clinical trial conversation belongs in the very first appointment.

A diagnosis of SCLC can trigger a whirlwind of appointments, tests, and decisions. But amid all that noise, there is one question patients should ask their doctor as early as possible:

“Is there a clinical trial that might be right for me?”

Many patients may associate that question with running out of treatment options. But according to Dr. Ashish Saxena, Chief of Thoracic Medical Oncology at Weill Cornell Medicine, that’s not always the case.

(NewsUSA) - In 2018, then-52-year-old Todd Repass Jr. stood up after a meal and immediately knew something was wrong. It was terrifying. He felt weak, short of breath, and, at times, dizzy. The eventual diagnosis – atrial fibrillation (AFib) – kicked off a nearly seven-year health journey, during which he leaned on his son, an employee of medical device manufacturer, Medtronic, for guidance. 

“You just have no clue what’s happening to you,” Todd recalls. “So, you’re confused, you’re scared.”

(Dr. Matthew Holman) - There is a piece of good public health news that deserves more attention: youth tobacco use in the United States has fallen to historically low levels. That progress did not happen by accident. It reflects years of prevention work, stronger age restrictions, public education, and a broad consensus that tobacco and nicotine products should not be used by anyone under the legal age.

(Peter Pitts, President and Co-founder of the Center for Medicine in the Public Interest ) - Consumers purchasing retatrutide online may think they are buying a safe, clinically tested weight-loss drug. They are not. Medical spas and online sellers have built a booming black market around an unapproved investigational drug – exploiting polished websites and professional packaging to sell illegal drugs to unsuspecting Americans. What is especially concerning about today’s version of this deception is how FDA is doing nothing to stop it, allowing this black market to turn into a digital-age Wild West.